G. G. Steger
IQVIA (France) · 98 works · 2,106 citations · h-index 21
Top works
- Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
- Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
- Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
- Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study
- Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
- Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.
- Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
- Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot stud
- Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
- Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
- Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF
- Complete remission of metastasisted clear cell sarcoma of tendons and aponeuroses
- Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
- The clinical course of lung metastases from breast cancer
- Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).
- A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
- Genetic analysis of multiple synchronous lesions of the colon adenoma–carcinoma sequence
- Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial
- Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer
- Escalating dose regimen of intraperitoneal mitoxantrone: Phase I study—clinical and pharmacokinetic evaluation